Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

Samantha Bowyer, P. Prithviraj, P. Lorigan, J. Larkin, G. Mcarthur, V. Atkinson, Michael Millward, M. Khou, S. Diem, S. Ramanujam, B. Kong, E. Liniker, A. Guminski, P. Parente, M.C. Andrews, S. Parakh, J. Cebon, G.V. Long, M.S. Carlino, O. Klein

    Research output: Contribution to journalArticle

    62 Citations (Scopus)

    Abstract

    © 2016 Cancer Research UK. Background:Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.Methods:We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1 therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3 mg kg -1 for a maximum of four doses.Results:Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (>6 months) stable disease. Thirty-five percent of patients developed grade 3-5 immune-related toxicity associated with ipilimumab therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade 3-5 pneumonitis leading to death in one patient.Conclusions:Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.
    Original languageEnglish
    Pages (from-to)1084-1089
    JournalBritish Journal of Cancer
    Volume114
    Issue number10
    DOIs
    Publication statusPublished - 2016

    Fingerprint Dive into the research topics of 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'. Together they form a unique fingerprint.

    Cite this